Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAN: Klarity CL in Dry Eye
NCT05322148Phase 3Completed
- Sponsor
- Research Insight
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of cyclosporine + loteprednol in dry eye syndrome (DED), sponsored by Research Insight. Started Jun 2022; status: completed.
02
Drugs
cyclosporine + loteprednol
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT05322148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322148.